Zai Lab (ZLAB) Total Non-Current Liabilities (2022 - 2026)
Zai Lab (ZLAB) posted Total Non-Current Liabilities of $433.7 million for Q1 2026, down 5.07% sequentially from $456.9 million in Q4 2025, and up 19.73% YoY from $362.3 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Zai Lab has reported Total Non-Current Liabilities for 5 years, with the latest figure at $433.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 19.73% year-over-year to $433.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $433.7 million (up 19.73% YoY) and the FY2025 annual result came in at $456.9 million, up 32.61% from the prior year.
- Total Non-Current Liabilities retreated to $433.7 million in Q1 2026 per ZLAB's latest filing, from $456.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $456.9 million in Q4 2025 and troughed at $162.4 million in Q3 2023.
- A 5-year average of $293.8 million and a median of $300.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities jumped 95.43% in 2024, then advanced 19.73% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $174.5 million in 2022, then soared by 37.42% to $239.9 million in 2023, then surged by 43.64% to $344.5 million in 2024, then soared by 32.61% to $456.9 million in 2025, then fell by 5.07% to $433.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $433.7 million, $456.9 million, and $398.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Zai Lab | 2.92 Bn | 2.21 Bn | 58.15 Mn | 467.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 467.53 Mn |
| Mar 31, 2026 | 433.72 Mn |
| Dec 31, 2025 | 456.88 Mn |
| Sep 30, 2025 | 398.67 Mn |
| Jun 30, 2025 | 372.04 Mn |
| Mar 31, 2025 | 362.25 Mn |
| Dec 31, 2024 | 344.53 Mn |
| Sep 30, 2024 | 317.35 Mn |
| Jun 30, 2024 | 282.86 Mn |
| Mar 31, 2024 | 225.94 Mn |
| Dec 31, 2023 | 239.85 Mn |
| Sep 30, 2023 | 162.39 Mn |
| Jun 30, 2023 | 173.73 Mn |
| Mar 31, 2023 | 168.51 Mn |
| Dec 31, 2022 | 174.55 Mn |